media,category,color,font,fontsize,fontcolor,edgewidth,edgecolor,nodeweight
Bindi et al (2013),Level5,black,2,5,black,0.5,black,0.5
Massoumi G et al (2018),Level5,black,2,5,black,0.5,black,0.5
Bartelmaos et al (2013),Level5,black,2,5,black,0.5,black,0.5
Carson JL et al (2021),Level5,black,2,5,black,0.5,black,0.5
Demeyere et al (2010),Level5,black,2,5,black,0.5,black,0.5
Goldstein et al (2015),Level5,black,2,5,black,0.5,black,0.5
Innerhofer et al (2017),Level5,black,2,5,black,0.5,black,0.5
Jost et al (2022),Level5,black,2,5,black,0.5,black,0.5
Moore et al (2018),Level5,black,2,5,black,0.5,black,0.5
Morrison et al (2019),Level5,black,2,5,black,0.5,black,0.5
Sarode et al (2013),Level5,black,2,5,black,0.5,black,0.5
Smith et al (2022),Level5,black,2,5,black,0.5,black,0.5
Sperry et al (2018),Level5,black,2,5,black,0.5,black,0.5
Steiner et al (2016),Level5,black,2,5,black,0.5,black,0.5
Stensballe et al (2018),Level5,black,2,5,black,0.5,black,0.5
Tollofsrud et al (2003),Level5,black,2,5,black,0.5,black,0.5
Yiu et al (2006),Level5,black,2,5,black,0.5,black,0.5
Zhang et al (20219),Level5,black,2,5,black,0.5,black,0.5
Chong Sung et al (2006),Level5,black,2,5,black,0.5,black,0.5
French et al (2003),Level5,black,2,5,black,0.5,black,0.5
Garrigue et al (2017),Level5,black,2,5,black,0.5,black,0.5
Green et al (2020),Level5,black,2,5,black,0.5,black,0.5
Pieters et al (2015),Level5,black,2,5,black,0.5,black,0.5
Karkouti et al (2021),Level5,black,2,5,black,0.5,black,0.5
Lance et al (2012),Level5,black,2,5,black,0.5,black,0.5
Tamura et al (2020),Level5,black,2,5,black,0.5,black,0.5
Etemadreziae et al (2007),Level5,black,2,5,black,0.5,black,0.5
Muller et al (2015),Level5,black,2,5,black,0.5,black,0.5
CA Physiological,Level1,black,2,5,black,3,black,94
CA Adverse events,Level1,black,2,5,black,3,black,29
CA Resource use,Level1,black,2,5,black,3,black,80
CA Life impact,Level1,black,2,5,black,3,black,15
CA Clinical,Level1,black,2,5,black,3,black,22
CA Death,Level1,black,2,5,black,3,black,14
D 2 Blood and lymphatic system outcomes,Level2,black,2,5,black,3,black,88
D 38 Adverse events and effects,Level2,black,2,5,black,3,black,29
D 22 Respiratory thoracic and mediastinal outcomes,Level2,black,2,5,black,3,black,3
D 36 Need for further intervention,Level2,black,2,5,black,3,black,65
D 25 Physical functioning,Level2,black,2,5,black,3,black,2
D 24 Vascular outcomes,Level2,black,2,5,black,3,black,20
D 32 Delivery of care,Level2,black,2,5,black,3,black,10
D 1 Mortality and Survival,Level2,black,2,5,black,3,black,14
D 34 Economic,Level2,black,2,5,black,3,black,1
D 17 Nervous system outcomes,Level2,black,2,5,black,3,black,4
D 11 Immune system outcomes,Level2,black,2,5,black,3,black,1
D 35 Hospital,Level2,black,2,5,black,3,black,16
D 30 Global quality of life,Level2,black,2,5,black,3,black,1
MC Otherlaboratory measurements,Level3,black,2,5,black,3,black,22
MC Measures of coagulation,Level3,black,2,5,black,3,black,57
MC Adverse events,Level3,black,2,5,black,3,black,32
MC Blood usage,Level3,black,2,5,black,3,black,50
MC Life impact,Level3,black,2,5,black,3,black,2
MC Bleeding,Level3,black,2,5,black,3,black,19
MC Other,Level3,black,2,5,black,3,black,4
MC Mortality,Level3,black,2,5,black,3,black,15
MC Organ specific treatment effect,Level3,black,2,5,black,3,black,7
MC Feasibility,Level3,black,2,5,black,3,black,6
MC Need for additional treatment,Level3,black,2,5,black,3,black,12
MC INR,Level3,black,2,5,black,3,black,13
MC Length of stay,Level3,black,2,5,black,3,black,15
OM Thromboelastography ,Level4,black,2,5,black,3,black,1
OM ACT,Level4,black,2,5,black,3,black,1
OM Adverse events,Level4,black,2,5,black,3,black,16
OM aPTT,Level4,black,2,5,black,3,black,9
OM arterial blood gas,Level4,black,2,5,black,3,black,4
OM ATIII,Level4,black,2,5,black,3,black,1
OM Avoidance of allogeneic transfusion,Level4,black,2,5,black,3,black,1
OM Barthel Index,Level4,black,2,5,black,3,black,1
OM Bleeding,Level4,black,2,5,black,3,black,4
OM Blood loss,Level4,black,2,5,black,3,black,6
OM Chest tube output,Level4,black,2,5,black,3,black,3
OM Coagulation factors ,Level4,black,2,5,black,3,black,11
OM Complement,Level4,black,2,5,black,3,black,1
OM Complete Blood Count,Level4,black,2,5,black,3,black,10
OM Consented and received intervention,Level4,black,2,5,black,3,black,1
OM Ddimers,Level4,black,2,5,black,3,black,2
OM Death,Level4,black,2,5,black,3,black,3
OM Donor exposure,Level4,black,2,5,black,3,black,1
OM Economic impact ,Level4,black,2,5,black,3,black,1
OM Electrolytes,Level4,black,2,5,black,3,black,1
OM Endothelial markers,Level4,black,2,5,black,3,black,1
OM Extended Glasgow Outcome Scale ,Level4,black,2,5,black,3,black,1
OM Feasibility,Level4,black,2,5,black,3,black,2
OM FFP,Level4,black,2,5,black,3,black,1
OM Fibrin monomer,Level4,black,2,5,black,3,black,1
OM Fibrinogen,Level4,black,2,5,black,3,black,11
OM Fluids,Level4,black,2,5,black,3,black,5
OM General,Level4,black,2,5,black,3,black,1
OM Glascow Coma Scale,Level4,black,2,5,black,3,black,1
OM HCT,Level4,black,2,5,black,3,black,2
OM Hemostatic agents,Level4,black,2,5,black,3,black,7
OM Hemostatic efficacy,Level4,black,2,5,black,3,black,3
OM in vivo thrombin generation ,Level4,black,2,5,black,3,black,1
OM Inflammation markers,Level4,black,2,5,black,3,black,1
OM INR,Level4,black,2,5,black,3,black,14
OM Intracerebral hemorrhage,Level4,black,2,5,black,3,black,2
OM Lenght of hospital stay,Level4,black,2,5,black,3,black,1
OM LOS Hospital,Level4,black,2,5,black,3,black,6
OM LOS ICU,Level4,black,2,5,black,3,black,8
OM LOS PICU,Level4,black,2,5,black,3,black,1
OM Lung injury,Level4,black,2,5,black,3,black,1
OM Major bleeding,Level4,black,2,5,black,3,black,2
OM Mortality,Level4,black,2,5,black,3,black,9
OM Mortality ,Level4,black,2,5,black,3,black,1
OM mRS score,Level4,black,2,5,black,3,black,1
OM National Institute of Health Stroke Scale,Level4,black,2,5,black,3,black,1
OM Need for massive transfusion,Level4,black,2,5,black,3,black,2
OM Other ,Level4,black,2,5,black,3,black,1
OM Plasma,Level4,black,2,5,black,3,black,14
OM Plasma thromboplastin time (PTT),Level4,black,2,5,black,3,black,1
OM plasma to crystalloid ratio,Level4,black,2,5,black,3,black,1
OM Platelets,Level4,black,2,5,black,3,black,13
OM Protein C and S,Level4,black,2,5,black,3,black,2
OM Prothrombin,Level4,black,2,5,black,3,black,1
OM Protocol adherence,Level4,black,2,5,black,3,black,1
OM PT,Level4,black,2,5,black,3,black,6
OM PTT,Level4,black,2,5,black,3,black,3
OM Pulmonary oedema,Level4,black,2,5,black,3,black,1
OM Quality of life,Level4,black,2,5,black,3,black,1
OM RBC,Level4,black,2,5,black,3,black,16
OM renal failure,Level4,black,2,5,black,3,black,1
OM Reoperation,Level4,black,2,5,black,3,black,4
OM Reptilase time,Level4,black,2,5,black,3,black,1
OM Reversal of coagulopathy,Level4,black,2,5,black,3,black,1
OM safety,Level4,black,2,5,black,3,black,1
OM Survival ,Level4,black,2,5,black,3,black,1
OM Thrombin generation,Level4,black,2,5,black,3,black,1
OM Time from intervention to chest closure,Level4,black,2,5,black,3,black,1
OM Time to intervention,Level4,black,2,5,black,3,black,1
OM Time to RBCtransfusion,Level4,black,2,5,black,3,black,1
OM Time to transfuion,Level4,black,2,5,black,3,black,1
OM traceability ,Level4,black,2,5,black,3,black,1
OM Transfusion reaction,Level4,black,2,5,black,3,black,6
OM Urgent surgery,Level4,black,2,5,black,3,black,1
OM Viscoelastic tests,Level4,black,2,5,black,3,black,4
OM Whole Blood,Level4,black,2,5,black,3,black,2
